Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 Expression
Biagio Ricciuti, MD, spoke about future analyses and major takeaways of a study analyzing outcomes with frontline immunotherapy based on PD-L1 expression in patients with non–small cell lung cancer.
Biagio Ricciuti, MD, Discusses Correlative Analysis of PD-L1 Expression in NSCLC Treated With Pembrolizumab Monotherapy
Biagio Ricciuti, MD, spoke about results of pembrolizumab monotherapy administration in patients with non–small cell lung cancer who had a PD-L1 tumor proportion score of 90% or more.
Biagio Ricciuti, MD, Talks About Prolonged Response to Pembrolizumab Monotherapy in PD-L1–High NSCLC
Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.
Biagio Ricciuti, MD, Reviews Combination Immunotherapy Regimens in NSCLC
Biagio Ricciuti, MD, spoke about combination immunotherapy regimens for patients with non–small cell lung cancer who did not respond well to prior treatment.
Biagio Ricciuti, MD, on Rationale for Analyzing Pembrolizumab Efficacy Relative to PD-L1 Expression in NSCLC
Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.
